Skip to main content

Terbinafine (Monograph)

Brand name: LamISIL
Drug class: Allylamines
- Squalene Epoxidase Inhibitors
Chemical name: (E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethanamine hydrochloride
Molecular formula: C21H25N
CAS number: 78628-80-5

Medically reviewed by Drugs.com on Apr 10, 2024. Written by ASHP.

Introduction

Antifungal; synthetic allylamine structurally and pharmacologically related to naftifine.1 2 3 10 11 25

Uses for Terbinafine

Onychomycosis

Treatment of dermatophyte infections of the toenail or fingernail (onychomycosis, tinea unguium) caused by susceptible fungi.1 27 28 29 30 31 32 33 34 35 65

Has been effective in treatment of nail infections caused by most strains of Trichophyton rubrum and T. mentagrophytes.1 27 28 29 30 31 32 33 34 35 Although usually active in vitro against Epidermophyton floccosum, Candida albicans, and Scopulariopsis brevicaulis, efficacy in treatment of onychomycosis caused by these organisms has not been established in adequate and controlled studies.1

Terbinafine may be particularly useful in patients who cannot tolerate azole antifungals (e.g., itraconazole) or when there are concerns regarding possible drug interactions between azoles and other drugs the patient is receiving.1 3 26 27 28 38 39 40 However, liver failure (sometimes leading to death or liver transplant) has occurred rarely in patients with or without preexisting liver disease who were receiving oral terbinafine for treatment of onychomycosis.1 60 71 72 (See Hepatotoxicity under Cautions.)

Tinea Capitis

Treatment of tinea capitis (scalp ringworm) caused by susceptible dermatophytes (e.g., Trichophyton, Microsporum).52 53 54 55 56 57 60 61 62 63 65 68 75 77 78 78 80 81 82

Tinea capitis requires treatment with an oral antifungal.54 55 61 62 65 68 75 77 78 Topical therapies (e.g., shampoos containing selenium sulfide, povidone iodine, or ketoconazole; topical antifungals) sometimes used as adjuncts to an oral antifungal and may reduce fungal shedding and the risk of transmission or reinfection.54 55 61 65 68 77 78

Oral griseofulvin is usual drug of choice;55 61 62 63 65 68 75 77 78 alternatives include oral fluconazole, itraconazole, or terbinafine.55 61 62 63 65 68 75 77

Oral terbinafine appears to be as effective as oral griseofulvin for treatment of tinea capitis caused by Trichophyton, and requires a shorter duration of treatment which may increase compliance.55 61 62 63 65 However, there is some evidence that griseofulvin may be more effective than terbinafine when M. canis is the causative agent.55 56 57 61 62 63

Tinea Corporis or Tinea Cruris

Treatment of tinea corporis† [off-label] (body ringworm)53 55 56 65 75 or tinea cruris† [off-label] (jock itch).65 75

Topical antifungals usually are effective for treatment of uncomplicated tinea corporis.55 65 73 74 75 76 An oral antifungal (griseofulvin, fluconazole, itraconazole, terbinafine) may be necessary if tinea corporis is extensive, dermatophyte folliculitis is present, the infection does not respond to topical therapy, or the patient is immunocompromised because of coexisting disease or concomitant therapy.55 65 73 74 75 76

Terbinafine Dosage and Administration

Administration

Oral Administration

Administer orally.1 60

Take oral granules with food.60 Sprinkle contents of single-dose packet on a spoonful of pudding or other soft, non-acidic food (e.g., mashed potatoes);60 do not use applesauce or fruit-based food.60 Swallow entire spoonful (without chewing).60 If dosage requires 2 packets for each dose, sprinkle contents of both packets on a single spoonful of nonacidic food or sprinkle contents of the packets on 2 spoonfuls of nonacidic food.60

Dosage

Available as terbinafine hydrochloride; dosage expressed in terms of terbinafine.1 60

Pediatric Patients

Tinea Capitis
Oral

Granules in children ≥4 years of age: 125–250 mg once daily for 6 weeks.60 Use 125 mg once daily in those weighing <25 kg, 187.5 mg once daily in those weighing 25–35 kg, and 250 mg once daily in those weighing >35 kg.60

Some evidence that a longer duration of treatment (e.g., 6–8 weeks) or higher dosage may be necessary when tinea capitis is caused by M. canis.57 61 65 68 77

Adults

Onychomycosis
Fingernails
Oral

Tablets: 250 mg daily given for 6 weeks.1 3 10 27 More prolonged treatment generally has not been more effective,33 although some patients may benefit from extended and/or repeated courses of terbinafine.3 29 33 50

Fingernail infections usually are reevaluated ≥18 weeks after completion of treatment.1 10 27 35

Toenails
Oral

Tablets: 250 mg daily given for 12 weeks.1 10 27 28 29 33 46 Some patients who do not respond to the initial 12-week regimen may respond to a second course.29

Toenail infections usually are reevaluated 6–9 months after completion of therapy.1 10 28 29

Tinea Capitis
Oral

Granules: 125–250 mg once daily for 6 weeks.60 Use 187.5 mg once daily in those weighing 25–35 kg and 250 mg once daily in those weighing >35 kg.60

Some evidence that a longer duration of treatment (e.g., 6–8 weeks) or higher dosage may be necessary when tinea capitis is caused by M. canis.57 61 65 68 77

Tinea Corporis† [off-label] or Tinea Cruris† [off-label]
Oral

Tablets: 250 mg daily for 2–4 weeks has been used.65 75

Special Populations

Hepatic Impairment

Not recommended in patients with preexisting liver disease (e.g., cirrhosis).1 (See Hepatic Impairment under Cautions.)

Renal Impairment

Not recommended in patients with renal impairment (i.e., Clcr ≤50 mL/minute) (See Renal Impairment under Cautions.)

Detailed Terbinafine dosage information

Cautions for Terbinafine

Contraindications

Warnings/Precautions

Warnings

Hepatotoxicity

Hepatotoxicity, including abnormal liver function tests and severe cholestatic hepatitis, reported in some patients receiving oral terbinafine.1 60 69 70 71 72

Liver failure, sometimes leading to death or liver transplant, occurred rarely in patients with or without preexisting liver disease receiving oral terbinafine for treatment of onychomycosis.1 60 71 72 Most patients had serious underlying systemic conditions;1 60 severity and outcome of hepatotoxicity may be worse in patients with active or chronic liver disease.1 60

Not recommended in patients with chronic or active liver disease.1 60

Assess hepatic function (serum AST and ALT) prior to initiation of oral terbinafine.1

Discontinue terbinafine if there is biochemical or clinical evidence of liver injury,1 60 including increased ALT or AST concentrations, persistent nausea, anorexia, fatigue, vomiting, right upper abdominal pain or jaundice, dark urine, or pale stools.1 60

Hematologic Effects

Transient decrease in absolute lymphocyte count (ALC) reported; clinical importance unknown.1 60 Severe neutropenia reported rarely; resolved with or without supportive therapy when terbinafine was discontinued.1 60

Thrombocytopenia,1 60 agranulocytosis,1 60 pancytopenia,60 and anemia60 reported during postmarketing surveillance; causal relationship not established.60

In patients with suspected immunodeficiency, consider monitoring CBCs if oral terbinafine is continued for >6 weeks.1 60

If clinical signs and symptoms suggest secondary infection, perform CBC.1 60 If neutrophil count is ≤1000/mm3, discontinue terbinafine and initiate supportive therapy.1 60

Dermatologic Effects

Serious skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis) reported rarely.1 60

Psoriasiform eruptions or exacerbation of psoriasis and acute, generalized exanthematous pustulosis reported.1 60 47

If progressive rash occurs, discontinue terbinafine.1 60

Lupus Erythematosus

Precipitation and exacerbation of cutaneous and systemic lupus erythematosus reported.1 60

If patient develops clinical signs and symptoms suggestive of lupus erythematosus, discontinue terbinafine.1 60

Sensitivity Reactions

Hypersensitivity Reactions

Angioedema and allergic reactions, including anaphylaxis, reported rarely.1 60

General Precautions

Ocular Effects

Visual disturbances, including changes in ocular lens and retina, reported following use of oral terbinafine tablets for treatment of onychomycosis in adults;1 60 clinical importance unknown.1 60

Although no ophthalmologic safety signal was identified in clinical trials using terbinafine oral granules, there were some reports of changes in visual acuity and some reports of color confusion in yellow-blue color vision assessments.60

GI Effects

Taste disturbances (including taste loss) may occur.1 60 Usually resolves within several weeks after terbinafine is discontinued, but prolonged (>1 year) taste disturbance has been reported.1 60 May be severe enough to result in decreased food intake leading to substantial and unwanted weight loss.1 60

Selection and Use of Antifungals for Onychomycosis

Prior to administration of oral terbinafine for treatment of onychomycosis, appropriate nail specimens for microbiologic studies (e.g., potassium hydroxide [KOH] preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis.1

When selecting an antifungal for treatment of onychomycosis, consider reported adverse effects and risk of serious effects, need for prolonged therapy, cost, and risk of relapse.27 48

Toenail infections generally require more prolonged antifungal therapy than fingernail infections.1 3 27 28 29 30 31 32 33 34 35

The optimal clinical effect of terbinafine in treatment of onychomycosis is not seen until several months after mycologic cure and completion of treatment, and is related to the period required for outgrowth of healthy nail.1 28 34 35

Possible Prescribing and Dispensing Errors

Ensure accuracy of prescription; similarity in spelling of lamotrigine (Lamictal) and terbinafine (Lamisil) may result in errors.58 59

Specific Populations

Pregnancy

Category B.1 60

Postpone use of oral terbinafine until after pregnancy is completed.1 60

Lactation

Distributed into milk.1 60 Use not recommended.1 60

Pediatric Use

Safety and efficacy of terbinafine tablets not established in children1 <18 years of age.51

Safety and efficacy of terbinafine oral granules not established in children <4 years of age.60

Geriatric Use

Terbinafine oral granules not studied in geriatric patients.60

Hepatic Impairment

Clearance may be decreased substantially (about 50%) in adults with hepatic cirrhosis.1 3 60

Not recommended in patients with chronic or active liver disease.1 27 60 (See Hepatotoxicity under Cautions.)

Renal Impairment

Clearance may be decreased substantially (about 50%) in adults with renal impairment (Clcr ≤50 mL/minute).1 3 60

Not adequately studied in patients with Clcr ≤50 mL/minute;1 27 60 use in such patients not recommended.1

Common Adverse Effects

GI effects (diarrhea, dyspepsia, nausea, vomiting, abdominal pain, taste disturbances),1 60 63 headache,60 63 fever,60 63 upper respiratory tract infection or symptoms (cough, nasopharyngitis, nasal congestion, pharyngolaryngeal pain, influenza),60 63 liver test abnormalities,1 dermatologic effects (rash, urticaria, pruritus).1 60

Drug Interactions

Inhibits CYP2D6.1 60

Drugs Metabolized by Hepatic Microsomal Enzymes

Pharmacokinetic interactions possible with drugs that are substrates for CYP2D6 (e.g., tricyclic antidepressants, β-blockers, selective serotonin reuptake inhibitors [SSRIs], monoamine oxidase [MAO] inhibitors); may be clinically important if the drug has a narrow therapeutic window.1 60 Monitor carefully if terbinafine is used concomitantly with such drugs; dosage of the drug metabolized by CYP2D6 may need to be reduced.1 60

Specific Drugs and Foods

Drug or Food

Interaction

Comments

Antiarrhythmic agents (amiodarone, flecainide, propafenone)

Potential increased antiarrhythmic concentrations1 60

Amiodarone: Possibility of substantially increased terbinafine concentrations and AUC60

Monitor carefully; reduced dosage of antiarrhythmic may be required1 60

Antidepressants

Concomitant use of terbinafine and antidepressants metabolized by CYP2D6 (e.g., tricyclics, SSRIs, MAO inhibitors) may result in increased concentrations of the antidepressant1 60

Desipramine: Increased concentration and AUC of desipramine; effect may persist ≥4 weeks after discontinuance of terbinafine1 60

Monitor carefully; reduced dosage of tricyclic, SSRI, or MAO inhibitor antidepressant may be required1 60

Antifungals, azoles

Fluconazole: Substantially increased terbinafine concentrations and AUC;60 effect on fluconazole pharmacokinetics not considered clinically important60

Ketoconazole: Possibility of substantially increased terbinafine concentrations and AUC60

Benzodiazepines

Midazolam: Terbinafine does not affect midazolam pharmacokinetics40

Triazolam: Terbinafine does not have a clinically important effect on triazolam pharmacokinetics39

Caffeine

Decreased clearance of caffeine1 60

Cimetidine

Decreased clearance of terbinafine1 60

Cyclosporine

Increased clearance of cyclosporine;1 60 no effect on terbinafine clearance1 60

Dextromethorphan

Increased dextromethorphan/dextromethorphan metabolite ratio in urine60

Digoxin

No effect on digoxin clearance1 60

Rifampin

Substantially increased terbinafine clearance1 60

Sulfamethoxazole

No clinically important effect on sulfamethoxazole pharmacokinetics60

Theophylline

No clinically important effect on theophylline pharmacokinetics60

Trimethoprim

No clinically important effect on trimethoprim pharmacokinetics60

Warfarin

Increase or decrease in PT reported; causal relationship not established1 60

Zidovudine

No clinically important effect on zidovudine pharmacokinetics60
Terbinafine drug interactions (more detail)

Terbinafine Pharmacokinetics

Absorption

Bioavailability

Granules: Peak serum concentrations and AUC (systemic exposure) in children 4–8 years of age exhibit considerable interindividual variability (36–64%).60

Tablets: Peak plasma concentrations attained within 1.4–2 hours.1 64 Bioavailability is 40% as the result of first-pass metabolism.1 Following multiple doses, steady-state peak concentrations and AUC are 25% higher than those reported following a single dose.1 Considerable interindividual variability in systemic exposure reported in adults or children.64

Food

Granules: Effect of food not studied.60

Tablets: Food increases AUC by <20%;1 not considered clinically important.3 50 51

Distribution

Extent

Terbinafine is highly lipophilic and keratophilic and distributes in high concentrations into stratum corneum, sebum, hair, and nail matrix, bed, and plate; persists in these tissues for several weeks to months after discontinuance.3 10 27 34 41 42 43

Distributed into milk.1 60

Plasma Protein Binding

>99%.1 60

Elimination

Metabolism

Rapidly and extensively metabolized by at least 7 CYP isoenzymes, including 2C9, 1A2, 3A4, 2C8, and 2C19.60

No metabolites with antifungal activity have been identified to date.1 60

Elimination Route

Approximately 70% of an oral dose eliminated in urine.1 60

Half-life

Terminal half-life of 200–400 hours; may represent slow elimination from tissues (e.g., skin, adipose).1

Following multiple doses of oral granules in children 4–8 years of age, mean effective half-life obtained from the observed accumulation was 26.7 or 30.5 hours for 125- or 187.5-mg doses, respectively.60

Special Populations

Clearance decreased by about 50% in adults with renal impairment (Clcr ≤50 mL/minute) or hepatic cirrhosis.1 3 60

Stability

Storage

Oral

Granules

25°C; may be exposed to 15–30°C.60

Tablets

<25°C in tight container.1 Protect from light.1

Actions and Spectrum

Advice to Patients

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Terbinafine Hydrochloride

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Granules

125 mg (of terbinafine) per packet

LamISIL

Novartis

187.5 mg (of terbinafine) per packet

LamISIL

Novartis

Tablets

250 mg (of terbinafine)*

Terbinafine Hydrochloride Tablets

LamISIL

Novartis

AHFS DI Essentials™. © Copyright 2024, Selected Revisions April 10, 2024. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Off-label: Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

1. Novartis. Lamisil (terbinafine hydrochloride) tablets prescribing information. East Hanover, NJ; 2005 Nov.

2. Petranyi G, Ryder NS, Stutz A. Allylamine derivatives: new class of synthetic antifungal agents inhibiting fungal squalene epoxidase. Science. 1984; 224:1239-41. http://www.ncbi.nlm.nih.gov/pubmed/6547247?dopt=AbstractPlus

3. Balfour JA, Faulds D. Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs. 1992; 43: 259-84.

4. Savin RC. Treatment of chronic tinea pedis (athlete’s foot type) with topical terbinafine. J Am Acad Dermatol. 1990; 23:786-9. http://www.ncbi.nlm.nih.gov/pubmed/2229524?dopt=AbstractPlus

5. Berman B, Ellis C, Leyden J et al. Efficacy of a 1-week, twice-daily regimen of terbinafine 1% cream in the treatment of interdigital tinea pedis. J Am Acad Dermatol. 1992; 26:956-60. http://www.ncbi.nlm.nih.gov/pubmed/1607415?dopt=AbstractPlus

6. Smith EB, Noppakun N, Newton RC. A clinical trial of topical terbinafine (a new allylamine antifungal) in the treatment of tinea pedis. J Am Acad Dermatol. 1990; 23:790-4. http://www.ncbi.nlm.nih.gov/pubmed/2229525?dopt=AbstractPlus

7. Greer DL, Jolly HW Jr. Treatment of tinea cruris with topical terbinafine. J Am Acad Dermatol. 1990; 23: 800-4. http://www.ncbi.nlm.nih.gov/pubmed/2229527?dopt=AbstractPlus

8. Millikan LE. Efficacy and tolerability of topical terbinafine in the treatment of tinea cruris. J Am Acad Dermatol. 1990; 23:795-9. http://www.ncbi.nlm.nih.gov/pubmed/2229526?dopt=AbstractPlus

9. Kagawa S. Clinical efficacy of terbinafine in 629 Japanese patients with dermatomycosis. Clin Exp Dermatol. 1989; 14:114-5. http://www.ncbi.nlm.nih.gov/pubmed/2689013?dopt=AbstractPlus

10. Shear NH, Villars VV, Marsolais C. Terbinafine: an oral and topical antifungal agent. Clin Dermatol. 1992; 9:487-95.

11. Lyman CA, Walsh TJ. Systemically administered antifungal agents: a review of their clinical pharmacology and therapeutic applications. Drugs. 1992; 44:9-35. http://www.ncbi.nlm.nih.gov/pubmed/1379913?dopt=AbstractPlus

12. Anon. Topical terbinafine for tinea infections. Med Lett Drugs Ther. 1993; 35:76-8. http://www.ncbi.nlm.nih.gov/pubmed/8341207?dopt=AbstractPlus

13. Smith EB. Topical antifungal drugs in the treatment of tinea pedis, tinea cruris, and tinea corporis. J Am Acad Dermatol. 1993; 28(5 Pt 1):S24-8. http://www.ncbi.nlm.nih.gov/pubmed/8496408?dopt=AbstractPlus

14. Ryder NS, Seidl G, Troke PF. Effect of the antimycotic drug naftifine on growth of and sterol biosynthesis in Candida albicans. Antimicrob Agents Chemother. 1984; 25:483-7. http://www.ncbi.nlm.nih.gov/pubmed/6375557?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=185557&blobtype=pdf

15. Petranyi G, Georgopoulos A, Mieth H. In vivo antimycotic activity of naftifine. Antimicrob Agents Chemother. 1981; 19:390-2. http://www.ncbi.nlm.nih.gov/pubmed/7247367?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=181442&blobtype=pdf

16. Georgopapadakou NH, Dix BA, Smith SA et al. Effect of antifungal agents on lipid biosynthesis and membrane integrity in Candida albicans. Antimicrob Agents Chemother. 1987; 31:46-51. http://www.ncbi.nlm.nih.gov/pubmed/3551826?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=174649&blobtype=pdf

17. Ryder NS. Specific inhibition of fungal sterol biosynthesis by SF 86-327, a new allylamine antimycotic agent. Antimicrob Agents Chemother. 1985; 27:252-6. http://www.ncbi.nlm.nih.gov/pubmed/4039119?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=176248&blobtype=pdf

18. Ryder NS. Effect of allylamine antimycotic agents on fungal sterol biosynthesis measured by sterol side-chain methylation. J Gen Microbiol. 1985; 131:1595-1602. http://www.ncbi.nlm.nih.gov/pubmed/3900280?dopt=AbstractPlus

19. Ryder NS, Dupong MC. Inhibition of squalene epoxidase by allylamine antimycotic compounds. Biochem J. 1985; 230:765-70. http://www.ncbi.nlm.nih.gov/pubmed/3877503?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1152681&blobtype=pdf

20. Hay RJ. Recent advances in the management of fungal infections. Quart J Med. 1987; 244:631-9.

21. Schuster I. The interaction of representative members from two classes of antimycotics—the azoles and the allylamines—with cytochromes P-450 in steroidogenic tissues and liver. Xenobiotica. 1985; 15:529-46. http://www.ncbi.nlm.nih.gov/pubmed/4036174?dopt=AbstractPlus

22. Ivessa E, Daum G, Paltauf F. Mechanism of action of naftifine. Mykosen. 1987; 30(Suppl 1):15-21.

23. Petranyi G. Preclinical evaluation of Exoderil (naftifine). Part I. Results of experimental studies of the antifungal activity profile. Mykosen. 1987; 30(Suppl 1):22-7.

24. Czok R. Preclinical evaluation of Exoderil (naftifine). Part II. Mechanism of action, absorption, metabolism and excretion. Mykosen. 1987; 30(Suppl 1):28-31. http://www.ncbi.nlm.nih.gov/pubmed/3550458?dopt=AbstractPlus

25. Ryder NS. Terbinafine: Mode of action and properties of the squalene oxidase inhibition. Br J Dematol. 1992; 126(Suppl 39): 2-7.

26. Brodell RT, Elewski BE. Clinical Pearl: Systemic antifungal drugs and drug interactions. J Am Acad Dermatol. 1995; 33:259-260. http://www.ncbi.nlm.nih.gov/pubmed/7622654?dopt=AbstractPlus

27. Anon. Terbinafine for onychomycosis. Med Lett drugs Ther. 1996; 38:72-4. http://www.ncbi.nlm.nih.gov/pubmed/8699988?dopt=AbstractPlus

28. Brautigam M, Nolting S, Schopf RE et al. Randomized double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. BMJ. 1995; 311:919-22. http://www.ncbi.nlm.nih.gov/pubmed/7580551?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2550920&blobtype=pdf

29. Watson A, Marley J, Ellis D et al. Terbinafine in onychomycosis of the toenail: a novel treatment protocol. J Am Acad Dermatol. 1995; 33:775-9. http://www.ncbi.nlm.nih.gov/pubmed/7593777?dopt=AbstractPlus

30. Faergemann J, Anderson C, Hersle K et al. Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. J Am acad Dermatol. 1995; 32:750-3. http://www.ncbi.nlm.nih.gov/pubmed/7722020?dopt=AbstractPlus

31. Tosti A, Piraccini BM, Stinchi C et al. Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J Am Acad Dermatol. 1996; 34:595-600. http://www.ncbi.nlm.nih.gov/pubmed/8601647?dopt=AbstractPlus

32. Hofmann H, Brautigam M, Weidinger G et al. Treatment of toenail onychomycosis: a randomized, duble-blind study with terbinafine and griseofulvin. Arch Dermatol. 1995; 131:919-22. http://www.ncbi.nlm.nih.gov/pubmed/7632064?dopt=AbstractPlus

33. van der Schroeff JG, Cirkel PKS, Crijns MB et al. A randomized treatment duration- finding study of terbinafine in onychomycosis. Br J Dermatol. 1992; 126(supp 39):36-9. http://www.ncbi.nlm.nih.gov/pubmed/1531927?dopt=AbstractPlus

34. Wong CK, Cho YL. Very short duration therapy with oral terbinafine for fingernail onychomycosis. Br J Dermatol. 1995; 133:329-47. http://www.ncbi.nlm.nih.gov/pubmed/7547412?dopt=AbstractPlus

35. Haneke E, Tausch I, Brautigam M et al. Short-duration treatment of fingenail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. J Am Acad Dermatol. 1995; 32:72-7. http://www.ncbi.nlm.nih.gov/pubmed/7822520?dopt=AbstractPlus

36. Hogan DJ. Short-duration treatment of fingenail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. J Am Acad Dermatol. 1995; 33:541- 2. http://www.ncbi.nlm.nih.gov/pubmed/7657888?dopt=AbstractPlus

37. Haneke E. Short-duration treatment of fingenail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. J Am Acad Dermatol. 1995; 33:542. http://www.ncbi.nlm.nih.gov/pubmed/7657889?dopt=AbstractPlus

38. Robbins B, Chang CT, Cramer JA et al. Safe coadministration of terbinafine and terfenadine: a placebo-controlled crossover study of pharmacokinetic and pharmacodynamic interactions in healthy volunteers. Clin Pharmacol Ther. 1996; 59:275-83. http://www.ncbi.nlm.nih.gov/pubmed/8653990?dopt=AbstractPlus

39. Varhe A, Olkkola KT, Neuvonen PJ. Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism. Br J Clin harmacol. 1996; 41:319-23.

40. Ahonen J, Olkkola KT, Neuvonen PJ. Effect of itraconzaole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in helathy volunteers. Br J Clin Pharmacol. 1995; 40:270-2. http://www.ncbi.nlm.nih.gov/pubmed/8527290?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1365108&blobtype=pdf

41. Faergermann J, Zehender H, Denouel J et al. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks. Acta Derm Venereol (Stockh). 1993; 73:305-9.

42. Munro CS, Rees JL, Shuster S. The unexpectedly rapid response of fngal nail infection to short duration therapy. Acta Derm Venereol (Stockh). 1992; 72:131-3.

43. Schatz F, Brautigam M, Dobrowski E et al. Nail incorporation kinetics of terbinafine in onychomycosis patients. Clin Exp Dermatol. 1995; 20:377-83. http://www.ncbi.nlm.nih.gov/pubmed/8593713?dopt=AbstractPlus

44. Shadomy S, Espinel-Ingroff A, Gebhart RJ et al. In vitro studies with SF 86-327, a new orally active allylamine derivative. J Med Veterinary Mycol. 1985; 23:125-32.

45. Sandoz Pharmaceuticals. Lamisil (terbinafine hydrochloride) 1% cream prescribing information. In: Physicians’ desk reference. 50th ed. Montvale, NJ: Medical Economics Co Inc; 1996:2265-6.

46. DeBacker M, DeKeyser P, DeVroey C et al. A 12-week treatment for dermatophytic toe onychomycosis: terbinafine 250 mg/day vs. itraconazole 200 mg/day—a double-blind comparative trial. Br J Dermatol. 1996; 134(Suppl 46):16-7. http://www.ncbi.nlm.nih.gov/pubmed/8763462?dopt=AbstractPlus

47. Dupin N, Gorin I, Djien V et al. Acute generalized exanthematous pustulosis induced by terbinafine. Arch Dermatol. 1996; 132:1253-4. http://www.ncbi.nlm.nih.gov/pubmed/8859047?dopt=AbstractPlus

48. Odom RB. New therapies for onychomycosis. J Am Acad Dermatol. 1996; 35:S26-30. http://www.ncbi.nlm.nih.gov/pubmed/8784308?dopt=AbstractPlus

49. Roberts DT. Current therapy for onychomycosis. J Dermatological Treat. 1990; 1(Suppl 2):49-50.

50. Reviewers’ comments (personal observations).

51. Sandoz, East Hanover, NJ: personal communication.

52. Kullavanijaya P, Reangchainam S, Ungpakorn R. Randomized single-blind study of efficacy and tolerability of terbinafine in the treatment of tinea capitis. J Am Acad Dermatol. 1997; 272-3.

53. Krafchick B, Pelletier J. The use of oral terbinafine (Lamisil) in children. Dermatology. 1997; 194(Suppl 1):43-4. http://www.ncbi.nlm.nih.gov/pubmed/9154402?dopt=AbstractPlus

54. Drake LA, Dinehart SM, Farmer ER et al. Guidelines of care for superficial mycotic infections of the skin: tinea capitis and tinea barbae. J Am Acad Dermatol. 1996; 34:290-4. http://www.ncbi.nlm.nih.gov/pubmed/8642096?dopt=AbstractPlus

55. American Academy of Pediatrics. 2006 Red Book: Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006.

56. Bruckbauer HR, Hofmann H. Systemic antifungal treatment of children with terbinafine. Dermatology. 1997; 195:134-6. http://www.ncbi.nlm.nih.gov/pubmed/9310719?dopt=AbstractPlus

57. Dragos V, Lunder M. Lack of efficacy of 6-week treatment of oral terbinafine for tinea capitis due to Microsporum canis in children. Pediatr Dermatol. 1997; 14:46-8. http://www.ncbi.nlm.nih.gov/pubmed/9050765?dopt=AbstractPlus

58. Pattishall EN. Dear healthcare provider letter regarding dispensing errors involving Lamictal (lamotrigine). Research Triangle Park, NC: GlaxoSmithKline; undated.

59. Pattishall EN. Dear healthcare provider letter regarding dispensing errors involving Lamictal (lamotrigine). Research Triangle Park, NC: GlaxoSmithKline; 2001 Aug.

60. Novartis. Lamisil (terbinafine) oral granules prescribing information. East Hanover, NJ; 2007 Sept.

61. González U, Seaton T, Bergus G et al. Systemic antifungal therapy for tinea capitis in children. Cochrane Database Syst Rev. 2007; :CD004685. http://www.ncbi.nlm.nih.gov/pubmed/17943825?dopt=AbstractPlus

62. Fleece D, Gaughan JP, Aronoff SC. Griseofulvin versus terbinafine in the treatment of tinea capitis: a meta-analysis of randomized, clinical trials. Pediatrics. 2004; 114:1312-5. http://www.ncbi.nlm.nih.gov/pubmed/15520113?dopt=AbstractPlus

63. Elewski BE, Cáceres HW, DeLeon L et al. Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: results of two randomized, investigator-blinded, multicenter, international, controlled trials. J Am Acad Dermatol. 2008; 59:41-54. http://www.ncbi.nlm.nih.gov/pubmed/18378354?dopt=AbstractPlus

64. Abdel-Rahman SM, Herron J, Fallon-Friedlander S et al. Pharmacokinetics of terbinafine in young children treated for tinea capitis. Pediatr Infect Dis J. 2005; 24:886-91. http://www.ncbi.nlm.nih.gov/pubmed/16220086?dopt=AbstractPlus

65. Gupta AK, Cooper EA. Update in antifungal therapy of dermatophytosis. Mycopathologia. 2008 Nov-Dec; 166:353-67.

66. Ghannoum MA, Wraith LA, Cai B et al. Susceptibility of dermatophyte isolates obtained from a large worldwide terbinafine tinea capitis clinical trial. Br J Dermatol. 2008; 159:711-3. http://www.ncbi.nlm.nih.gov/pubmed/18510668?dopt=AbstractPlus

68. Möhrenschlager M, Seidl HP, Ring J et al. Pediatric tinea capitis: recognition and management. Am J Clin Dermatol. 2005; 6:203-13. http://www.ncbi.nlm.nih.gov/pubmed/16060708?dopt=AbstractPlus

69. Zapata Garrido AJ, Romo AC, Padilla FB. Terbinafine hepatotoxicity. A case report and review of literature. Ann Hepatol. 2003 Jan-Mar; 2:47-51.

70. Ajit C, Suvannasankha A, Zaeri N et al. Terbinafine-associated hepatotoxicity. Am J Med Sci. 2003; 325:292-5. http://www.ncbi.nlm.nih.gov/pubmed/12792250?dopt=AbstractPlus

71. Perveze Z, Johnson MW, Rubin RA et al. Terbinafine-induced hepatic failure requiring liver transplantation. Liver Transpl. 2007; 13:162-4. http://www.ncbi.nlm.nih.gov/pubmed/17192859?dopt=AbstractPlus

72. Agarwal K, Manas DM, Hudson M. Terbinafine and fulminant hepatic failure. N Engl J Med. 1999; 340:1292-3. http://www.ncbi.nlm.nih.gov/pubmed/10215503?dopt=AbstractPlus

73. Gupta AK, Einarson TR, Summerbell RC et al. An overview of topical antifungal therapy in dermatomycoses: a North American perspective. Drugs. 1998; 55:645-74. http://www.ncbi.nlm.nih.gov/pubmed/9585862?dopt=AbstractPlus

74. Piérard GE, Arrese JE, Piérard-Franchimont C. Treatment and prophylaxis of tinea infections. Drugs. 1996; 52:209-24. http://www.ncbi.nlm.nih.gov/pubmed/8841739?dopt=AbstractPlus

75. Hay RJ. Dermatophytosis and other superficial mycoses. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practices of infectious disease. 6th ed. Philadelphia, PA: Churchill Livingston; 2005.

76. Drake LA, Dincehart SM, Farmer ER et al. Guidelines of care for superficial mycotic infections of the skin: tinea corporis, tinea cruris, tinea faciei, tinea manuum, and tinea pedis. J Am Acad Dermatol. 1996; 34:282-6. http://www.ncbi.nlm.nih.gov/pubmed/8642094?dopt=AbstractPlus

77. Ali S, Graham TA, Forgie SE. The assessment and management of tinea capitis in children. Pediatr Emerg Care. 2007; 23:662-5; quiz 666-8. http://www.ncbi.nlm.nih.gov/pubmed/17876261?dopt=AbstractPlus

78. Abdel-Rahman, Nahata MC. Treatment of tinea capitis. Ann Pharmacother. 1997; 31:338-48. http://www.ncbi.nlm.nih.gov/pubmed/9066943?dopt=AbstractPlus

79. Haroon TS, Hussain I, Aman S et al. A randomized double-blind comparative study of terbinafine for 1, 2 and 4 weeks in tinea capitis. Br J Dermatol. 1996; 135:86-8. http://www.ncbi.nlm.nih.gov/pubmed/8776365?dopt=AbstractPlus

80. Jahangir M, Hussain I, Ul Hasan M et al. A double-blind, randomized, comparative trial of itraconazole versus terbinafine for 2 weeks in tinea capitis. Br J Dermatol. 1998; 139:672-4. http://www.ncbi.nlm.nih.gov/pubmed/9892912?dopt=AbstractPlus

81. Friedlander SF, Aly R, Krafchik B et al. Terbinafine in the treatment of Trichophyton tinea capitis: a randomized, double-blind, parallel-group, duration-finding study. Pediatrics. 2002; 109:602-7. http://www.ncbi.nlm.nih.gov/pubmed/11927703?dopt=AbstractPlus

82. Lipozencic J, Skerlev M, Orofino-Costa R et al. A randomized, double-blind, parallel-group, duration-finding study of oral terbinafine and open-label, high-dose griseofulvin in children with tinea capitis due to Microsporum species. Br J Dermatol. 2002; 146:816-23. http://www.ncbi.nlm.nih.gov/pubmed/12000378?dopt=AbstractPlus

Frequently asked questions

View more FAQ

Medical Disclaimer